- Home
- PERF vs ADAP Comparison
PERF vs ADAP Comparison
Compare PERF & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PERF
- ADAP
- Stock Information
- Founded
- PERF 2015
- ADAP 2008
- Country
- PERF Taiwan
- ADAP United Kingdom
- Employees
- PERF N/A
- ADAP N/A
- Industry
- PERF Computer Software: Prepackaged Software
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- PERF Technology
- ADAP Health Care
- Exchange
- PERF Nasdaq
- ADAP Nasdaq
- Market Cap
- PERF 205.7M
- ADAP 299.0M
- IPO Year
- PERF N/A
- ADAP 2015
- Fundamental
- Price
- PERF $1.86
- ADAP $1.09
- Analyst Decision
- PERF Hold
- ADAP Strong Buy
- Analyst Count
- PERF 2
- ADAP 3
- Target Price
- PERF $3.75
- ADAP $3.38
- AVG Volume (30 Days)
- PERF 7.3K
- ADAP 1.5M
- Earning Date
- PERF 10-22-2024
- ADAP 08-12-2024
- Dividend Yield
- PERF N/A
- ADAP N/A
- EPS Growth
- PERF N/A
- ADAP N/A
- EPS
- PERF 0.06
- ADAP N/A
- Revenue
- PERF $56,867,000.00
- ADAP $141,459,000.00
- Revenue This Year
- PERF $16.24
- ADAP $172.21
- Revenue Next Year
- PERF $14.29
- ADAP N/A
- P/E Ratio
- PERF $31.22
- ADAP N/A
- Revenue Growth
- PERF 16.64
- ADAP 99.90
- 52 Week Low
- PERF $1.70
- ADAP $0.42
- 52 Week High
- PERF $4.00
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- PERF 36.30
- ADAP 44.14
- Support Level
- PERF $1.85
- ADAP $1.17
- Resistance Level
- PERF $2.10
- ADAP $1.32
- Average True Range (ATR)
- PERF 0.07
- ADAP 0.09
- MACD
- PERF -0.02
- ADAP -0.01
- Stochastic Oscillator
- PERF 3.70
- ADAP 22.58
About PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions that are ultra-personalized, interactive and engaging, from online to in-store through beauty mirrors. Geographically, the company has a presence in the United States, France, Japan and Others.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.